Member Info for Kaneonaim

*************+sg9rk41i0af49bfs

Screw over shareholders then reward yourselves for doing so. Great business!

As pointed out earlier fab have taken a 3.68% holding in CMH not sure why it took them roughly 6 weeks to notify the market. Thinking we might see the same here possibly waiting for the dust to settle. I thought you had 3 days?? Guess certain individuals don’t have to play by the rules!

5. Date on which the threshold was crossed or reached vi:

15 January 2024

6. Date on which issuer notified (DD/MM/YYYY): 27th February 2024

Orchestrated for certain individuals to load up at a significant market discount and contradicting comments made in past rns’s.

Feel free to add any I’ve missed out.

GLA!!

Presentations have been presented to a select few. Made public then removed with no reasonable explanation.

The company has no pr and relies on shareholders sharing information on bulletin boards. Sometimes posters have shared information about the company before they have, showing a lack of interest or enthusiasm to maximise ALL shareholder value.

The company has recently chosen to issue price sensitive information via social media platforms rather than issue rns. Meaning not all shareholders could have access to the information and again the company relying on the information to be passed on via bulletin boards or telegram groups.

The CEO issued half/final reports stating the companies share price is undervalued and described how:

“We believe that the cumulative accretion of value during this time is not adequately reflected in the current market valuation of the Company, and we are now considering how best to address this anomaly.”

“The key drivers are all shareholders, who have had to become accustomed to the vagaries of the stock market and how it values the Company`s shares. Oftentimes the market capitalization of the Company has changed over a small number of trading days by 10-25% without any discernable reason”

Also the CEO stated:

“More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods”

“Our objective for the remainder of the year is to convert as many of the 45 sites currently evaluating IB Software”

Either they made no sales from 45 leads or have chosen not to disclose any new sales. As nothing has been reported to shareholders since these reports.

From a recent rns shareholder letter we were told.

“We have identified a large new grant opportunity that is specific to our core imaging technologies, and we are evaluating potential aims for a February submission.”

Again another comment that has been issued via an rns but nothing more has been spoken of. Meaning shareholders are just supposed to forget they said it.

Either the company and its board of directors are seriously out of its depth in managing shareholder expectations or they are not interested in maximising ALL shareholder value and are only interested in looking after themselves.

So after roughly 6 months of being told one thing and the company doing the opposite they announced to the market a placing raising £300k at 1.5p. How is this maximising all shareholder value this raise is a direct contradiction of the comments made in official documents. This price is roughly an 80% discount to the market price at the beginning of January. It will be interesting to see who has taken the placing when these shares are issued on 1st March. If we get to see. Potentially proving further that the recent price crash has been orchestrated

“Call a EGM with a single resolution, to remove the CEO, you need a group holding 5% to do this, might be easier to simply sell. The publicity will spur even if you have to withdraw the resoltution, there is lots on this area if you research similar cases”

This was Trevor’s advice to feedback plc shareholders on the advfn board that he regularly posts abuse at them on.

I’m sure between us we have well over over 5%. We could even remove the bent brokers and appoint new ones.

I’ve been in here a long time and am happy to admit when I break even I’m out as all trust is lost and I will avoid anything he or even peterhouse are involved with in the future. The disrespect shown here in the last couple months added with the comments in the final/half year results show that what they say and do are 2 different things and unfortunately now whatever they release by rns I won’t fully trust. Not that they even care about releasing rns’s as most of the news recently has been released on twitter.

Also does anyone else think that video the other week was released not for us but for those taking the placing. It will probably be released again. With regards to people thinking who has taken the placing imo we won’t see any tr1s as normally the include this information in the placing rns, whether it’s tb or anyone else and like most rns this was vague.

GLA!!! I think we may need it

220m shares not 320m

The key drivers are all shareholders, who have had to become accustomed to the vagaries of the stock market and how it values the Company`s shares. Oftentimes the market capitalization of the Company has changed over a small number of trading days by 10-25% without any discernable reason, however we remain firmly focused on the medium-term commercial prospects for our unique products and are confident that shareholder patience will be eventually rewarded.

It is five years since IQ-AI acquired Imaging Biometrics. Throughout that time the IB team have worked continuously and intensively to innovate and develop what has now become a valuable portfolio of medical IP. We believe that the cumulative accretion of value during this time is not adequately reflected in the current market valuation of the Company, and we are now considering how best to address this anomaly.

More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients.

 

It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023.

Our objective for the remainder of the year is to convert as many of the 45 sites currently evaluating IB Software, to client status though sales and to harness the momentum from the Phase 1 clinical trial to accelerate the planning for a Phase 2 trial.

These are all quotes taken from the half year and final reports. Whatever happened to the 45 sites evaluating IB software? Either they’ve converted some into sales and not told us (ALL SHAREHOLDERS) or 45 sites said no. Since these comments the share price has fallen off a cliff and there’s obviously a reason but this reason is not being relayed to ALL SHAREHOLDERS. Why? I just don’t understand the games being played. We listed on the us market and had no interest because we didn’t do any pr at all. Now we’ve got the same problem. If you want to run this company as a private company then do it but you will have to buy us out first until then have some self respect and update your shareholders. I don’t understand publicly saying one thing and then doing the complete opposite. You are just making yourself look like a tit!!

Published - a practical guide for DSC-MRI perfusion imaging from the #SchmaindaLab at

@MedicalCollege

. Grateful to have such a DSC powerhouse in IB's corner!

https://www.frontiersin.org/articles/10.3389/fradi.2024.1307586

Sorry yes I did get a response. It just said the video was made public by error they’re looking into see if they can repost it.

It was uploaded by imaging biometrics to the imaging biometrics page on YouTube.

The newly updated video has now been removed? I’ve messaged to ask why seems odd

Al's Comment:

We awarded a $100,000 grant to get this expanded access program for oral gallium maltolate launched. I will let you know when it opens. We helped fund the early work on this drug and early results look good. If interested in trying to get access, send an email to eap@imagingbiometrics.com and tell them a little about your case and ask if you may qualify for the program and to get on the waiting list. Our grant only covers the startup of the program and the first 15 patients. If any other organizations want to help fund the next group of patients, contact me!

https://virtualtrials.org/newsarticle.cfm?item=8568

50p I’d be happy with 5p at the moment lol!!

What I find strange is they completely ignore the fact about a partner for phase 2 which they have mentioned in the past. although they do mention

“Finally, every

indication is that a phase 2 trial is imminent, and we are preparing to continue our sponsorship. We will be

working very closely with the clinical team as they define the protocol and size of phase 2 and identify

other participating sites. There will be a gap between the conclusion of phase 1 and phase 2. Data

analysis and documentation needs to be submitted to the FDA and the phase 2 protocol needs FDA

approval. This makes an EAP even more strategic as it enables an aggressive pathway to continue our

efforts towards full commercialization.”

Does this mean they’re going it alone?

It was good to get an update regarding IB zero also. But still strange they decided to release it on x on a Sunday night which probably means we won’t get an rns.

Tyke you’re missing this part

Third, additional data from the EAP would be obtained faster than

the traditional phased trial pathway and would be considered “real-world-data” (RWD). RWD is

increasingly valued as it is a truer representation of the normal population of patients. RWD can also

identify critical information, such as biomarkers, that can significantly influence the size, scope, and cost

of subsequent phases. This data could then be used in a New Drug Application (NDA) to the FDA. In fact,

there have been agents approved by the FDA that relied solely on EAP data, and even more agents

whose approval relied primarily on data obtained from EAPs.

Basically I interpret it to mean the data(results) from the early access program could be used instead of having to complete a phase 3 trial and even explains the fda have approved drugs solely from esp data.

Dear Shareholders,

As we embark on a new year, I am pleased to provide this summary to you. In it you will find highlights

from 2023 and our plans for Q1, 2024.

Clinical Trial Update

The phase 1 trial being conducted at the Medical College of Wisconsin (MCW) continues to warrant our

full attention. Patients are enrolling at the 2000 mg dose level and are experiencing no significant side

effects. The goal of phase 1 is still unmet in that the maximum tolerated dose (MTD) has yet to be

determined. The clinical team is reviewing all data and discussing what, if any, criteria could be used in

lieu of MTD to define the recommended phase 2 dose (RP2D). This would then result in phase 1 being

closed and allow the preparation for a phase 2 trial to hit full stride.

While the phase 1 trial maintains momentum, significant regulatory milestones have been achieved that

formally validate the promising potential of GaM (as well as remind us of the lack of viable treatment

alternatives for brain tumor patients). In late December, the FDA designated the development of oral GaM

for the “treatment of adult patients with relapsed or refractory glioblastoma, IDH-wildtype” as Fast Track.

The Fast Track Designation (FTD) process facilitates the development of new drugs that treat serious

conditions and fill unmet clinical needs. Going forward, we intend to fully leverage the increased

communication and collaboration with the US FDA afforded by this process.

Along with the two Orphan Drug Designations (ODD) received last year, these regulatory

accomplishments have boosted the enthusiasm of our internal team and that of the leadership at the

Medical College of Wisconsin (MCW). Motivated by these accomplishments, we are launching an

Expanded Access Program (EAP). The benefits of an EAP are multi-faceted, and I will touch upon a few

significant ones here. First, the agent itself is very stable and does not require special storage or

handling. Thus, an oral agent that can be taken at home is an ideal candidate for executing an EAP.

Second, the EAP would make the agent accessible to patients throughout the U.S. and allow patients to

obtain GaM who otherwise could not participate, due to proximity to MCW or the inclusion/exclusion

criteria of the phase 1, etc. Based on the data obtained from phase 1, albeit limited, we believe the agent

has potential benefit for these patients. Third, additional data from the EAP would be obtained faster than

the traditional phased trial pathway and would be considered “real-world-data” (RWD). RWD is

increasingly valued as it is a truer representation of the normal population of patients. RWD can also

identify critical information, such as biomarkers, that can significantly influence the size, scope, and cost

of subsequent phases. This data could then be used in a New Drug Application (NDA) to the FDA. In fact,

there have been agents approved by the FDA that relied solely on EAP data, and even more agen

Apologies think it’s from yesterday

At 11:19 today price 3.30